• Advances in Small-Molecule Activation of Human Mitochondrial

  2026-08-06

  Recent work by Shu et al. provides a comprehensive analysis of small-molecule strategies for selectively activating human mitochondrial serine protease ClpP (hClpP), with a focus on structure–activity relationships and anticancer applications. Their synthesis of design principles and pharmacological data offers a foundation for translational research targeting mitochondrial proteostasis and metabolism.

• ARCA Cy5 EGFP mRNA (5-moUTP): Redefining Precision in mRNA D

  2026-08-06

  Explore how ARCA Cy5 EGFP mRNA (5-moUTP) leverages 5-methoxyuridine modification and advanced fluorescent labeling for unmatched mRNA localization and translation efficiency assays. This article uniquely analyzes product-specific advantages and translates recent nanoparticle delivery innovations into practical assay decisions.

• Pcbp1 Regulates Mitochondrial Integrity for Antibody Product

  2026-08-05

  Zhu et al. identify the RNA-binding protein Pcbp1 as a critical regulator of mitochondrial function and protein synthesis in B cells, directly linking posttranscriptional control to antibody production and germinal center responses. Their mechanistic work clarifies how mitochondrial integrity, mediated via Fdxr mRNA regulation, supports humoral immunity and provides a foundation for targeted investigation of B cell metabolism.

• Dual-Action Kinase Inhibitors Accelerate p38α MAPK Dephospho

  2026-08-05

  The reference study reveals that certain kinase inhibitors, including Losmapimod analogs, not only block p38α MAPK enzymatic activity but also enhance its dephosphorylation by stabilizing a conformation preferred by phosphatases. This dual-action mechanism opens new avenues for inflammation and vascular research, offering a path toward more selective and potent therapeutic strategies.

• Taltirelin Acetate: Protocols and Pitfalls for Neurodegenera

  2026-08-04

  Taltirelin acetate, a selective TRHR1 agonist, drives robust neuroprotection and dopaminergic modulation in preclinical models. This article distills cutting-edge findings into actionable protocols for Parkinson’s, itch, and sleep apnea studies, with troubleshooting advice for reproducible results.

• N-MYC/eIF4G1 Axis Drives Survival in inv(16) AML: Mechanisti

  2026-08-04

  Peramangalam et al. reveal that N-MYC sustains inv(16) acute myeloid leukemia (AML) survival by regulating eIF4G1, a previously unreported oncogenic target in AML. This study elucidates how targeting the CBFβ-SMMHC fusion protein disrupts the N-MYC/eIF4G1 axis, providing a rationale for new therapeutic strategies and advancing acute myeloid leukemia research.

• CFDA SE (carboxyfluorescein diacetate succinimidyl ester) Ce

  2026-08-03

  The CFDA SE Cell Tracer Kit addresses the need for stable, long-term fluorescent cell labeling in proliferation and lineage tracing studies. It should be used when durable, covalent cell staining is required and is not suitable for short-term or reversible labeling applications.

• Technical Guide to Hoechst 33342/PI Double Staining Kit (K22

  2026-08-03

  The Hoechst 33342/PI Double Staining Kit enables direct, fluorescence-based discrimination of viable, apoptotic, and necrotic cells by assessing chromatin condensation and membrane integrity. This kit is intended for research workflows, particularly in microscopy-based cell death analysis, and is not suitable for diagnostic or clinical applications.

• Vasopressin Analogues: Multitasking Roles and Lypressin Insi

  2026-08-02

  Glavaš et al. provide a comprehensive review of vasopressin and its analogues, with special attention to their structural modifications, pharmacological versatility, and emerging roles beyond traditional antidiuretic therapy. The work highlights how natural peptide analogues such as lypressin acetate enable both established and innovative research in vasoconstriction, diabetes insipidus, and antiviral applications.

• Targeted Hypothermic Albumin Perfusion Mitigates Ischemic Br

  2026-08-01

  This study demonstrates that intra-arterial selective hypothermic human serum albumin infusion (IA-SCAI) provides superior neuroprotection after cerebral ischemia-reperfusion in rats. By inhibiting the ROCK1/MLC pathway and reducing F-actin expression, this approach offers a mechanistically distinct strategy for improving outcomes in acute ischemic stroke.

• UTP Solution in Epigenetics: Empowering Precision RNA Resear

  2026-07-31

  Explore how high-purity UTP Solution (100 mM) advances translational research at the interface of transcription, epigenetics, and sensory biology. This thought-leadership article integrates mechanistic insights—from recent discoveries on olfactory receptor gene regulation—to strategic workflow guidance, positioning APExBIO’s UTP Solution as a transformative RNA amplification reagent for next-generation molecular biology.

• Naloxone Hydrochloride: Beyond Opioid Antagonism in Research

  2026-07-31

  Explore the advanced scientific applications of Naloxone hydrochloride as a potent opioid receptor antagonist, including its impact on neural stem cell proliferation and addiction pathways. Discover new insights and practical protocols for research assays.

• Parathyroid hormone (1-34) (human) in Bone and Kidney Resear

  2026-07-30

  Parathyroid hormone (1-34) (human) unlocks high-fidelity modeling of bone metabolism and chronic kidney disease–related calcification through nanomolar-potency receptor activation. Leverage this APExBIO peptide fragment for reproducible, quantitative insights in experimental workflows and advanced disease models.

• Telmisartan in Cardiovascular Disease: Beyond AT1R Blockade

  2026-07-30

  Explore Telmisartan as an angiotensin II receptor antagonist for advanced hypertension research. This article uniquely dissects Telmisartan's molecular pharmacology and its pivotal role in dissecting cardiac hypertrophy signaling, providing a deeper comparative analysis with alternative pathways and assay decision-making.

• Bedaquiline: Diarylquinoline Antibiotic for MDR-TB & Cancer

  2026-07-29

  Bedaquiline is a diarylquinoline antibiotic with dual action against multi-drug resistant tuberculosis and cancer stem cell metabolism. It targets Mycobacterium tuberculosis F1FO-ATP synthase and disrupts mitochondrial energy pathways, supporting its use in advanced infectious disease and oncology research.

15762 records 1/1051 page Next 12345 下5页 Last page